Treating age-related multimorbidity: the drug discovery challenge

Christos Ermogenous, Charlotte Green, Thomas Jackson, Michael Ferguson, Janet M. Lord (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)
126 Downloads (Pure)


Patients with multimorbidities have shorter life expectancy and their clinical management is more complex and expensive for healthcare systems currently focused on treating single diseases. Given that age is the major risk factor for multimorbidity, the challenge of treating these patients will only increase in coming years. Here, we review the case for targeting the core processes that drive the ageing phenotype as a novel pharmaceutical approach to multimorbidity. There is growing evidence that targeting ageing mechanisms can reduce or delay age-related diseases in animal models, and the first reports of clinical trials are now appearing. Although these trials currently focus on repurposed drugs, we propose several novel targets that would more specifically target ageing processes and thereby reduce multimorbidity and polypharmacy in future generations.

Original languageEnglish
Pages (from-to)1403-1415
Number of pages13
JournalDrug Discovery Today
Issue number8
Early online date20 Jun 2020
Publication statusPublished - Aug 2020

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Treating age-related multimorbidity: the drug discovery challenge'. Together they form a unique fingerprint.

Cite this